Reviewer | Employment | Research Grant | Other Research Support | Speakers’ Bureau/Honoraria | Expert Witness | Ownership Interest | Consultant/Advisory Board | Other |
---|---|---|---|---|---|---|---|---|
Robert M. Carey | University of Virginia Health System | NIH† | None | None | None | None | None | None |
Gregory D. Fink | Michigan State University | NIH† (money paid to institution); AHA† (money paid to institution); Medtronic* | None | None | None | None | None | None |
John M. Flack | Wayne State University | NIH*; Novartis*; Medtronic* | None | Novartis† | None | None | Novartis†; NIH*; Medtronic*; Back Beat Hypertension*; NIVasc* | None |
Daniel W. Jones | University of Mississippi | None | None | None | None | None | None | None |
Janet Wright | CDC | None | None | None | None | None | None | None |
This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10,000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10,000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
Modest.
Significant.